IP Library Granted Patent US 9,198,895
Granted Patent B2
US 9,198,895 · App. 14/589,941 · Granted Dec 1, 2015

Chroman derivatives, medicaments and use in therapy

Inventors: Andrew Heaton (Abbotsford, AU); Alan Husband (McMahon's Point, AU)
Assignee: MEI Pharma, Inc.
A61K31/353A61K31/282A61K31/337A61K31/37A61K31/655A61K31/7068A61K33/24A61K41/0038
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,198,895
App. No.
14/589,941
Granted
Dec 1, 2015
Kind
B2
Abstract

Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.

Claims (20)

1. A method of treating cancer, the method comprising administering to a subject in need thereof a compound of the formula (I-a):

wherein

R 1 is alkyl;

R 2 and R 3 are independently hydrogen, hydroxy, alkoxy, halo, or alkyl, with the exception that R 2 and R 3 are not both hydrogen; and

R 4 , R 5 and R 6 are independently hydrogen, hydroxy, alkoxy, or alkyl;

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the cancer is of epithelial, mesenchymal, or neural origin.

3. The method of claim 2 , wherein the cancer is ovarian cancer, breast cancer, pancreatic cancer, or melanoma.

4. The method of claim 1 , wherein administering the compound of formula (I-a) results in the cancer being sensitized to one or more chemotherapeutic agent or radiotherapy, and the method further comprises administering to the subject a chemotherapeutic agent or radiotherapy to which the cancer has been sensitized.

5. The method of claim 4 , wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, paclitaxel, gemcitabine, doxorubicin, decarbazine, or topotecan.

6. A method of sensitizing a cancer cell, the method comprising contacting the cancer cell with a compound of formula (I-a):

wherein

R 1 is alkyl;

R 2 and R 3 are independently hydrogen, hydroxy, alkoxy, halo or alkyl, with the exception that R 2 and R 3 are not both hydrogen; and

R 4 , R 5 and R 6 are independently hydrogen, hydroxy, alkoxy, or alkyl;

or a pharmaceutically acceptable salt thereof.

7. The method of claim 6 , wherein the cancer is of epithelial, mesenchymal, or neural origin.

8. The method of claim 7 , wherein the cancer is ovarian cancer, breast cancer, pancreatic cancer, or melanoma.

9. The method of claim of 6 , wherein the method of sensitizing comprises sensitizing the cancer cell to a chemotherapeutic agent to which, prior to the method of sensitizing, the cancer cell is not sensitive or is poorly sensitive.

10. The method of claim 6 , wherein the method of sensitizing comprises sensitizing the cancer cell to radiotherapy to which, prior to the method of sensitizing, the cancer cell is not sensitive or is poorly sensitive.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2015
From: HEATON, ANDREW; HUSBAND, ALAN
To: NOVOGEN RESEARCH PTY LTD
Reel/Frame 036452/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2015
From: NOVOGEN LIMITED
To: MARSHALL EDWARDS, INC.
Reel/Frame 036452/0714 →
CHANGE OF NAME Recorded Aug 28, 2015
From: MARSHALL EDWARDS, INC.
To: MEI PHARMA, INC.
Reel/Frame 036505/0218 →
Priority Claims (3)
JP 2004-315009 · Oct 29, 2004 · national
AU 2004-906363 · Nov 5, 2004 · national
WO PCT/AU2004/001619 · Nov 19, 2004 · international
Continuity (7)
Continuation 13891975 · May 10, 2013
Continuation 13415697 · Mar 8, 2012
Continuation 13231794 · Sep 13, 2011
Division 11230505 · Sep 21, 2005
Provisional Application 60611299 · Sep 21, 2004
Provisional Application 60676934 · May 3, 2005
Related Publication 20150238458A1 · Aug 27, 2015